|
000
| 01947nam##2200325za#4500 |
|---|
| 001 | 9.574624 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20210624184256 |
|---|
| 007 | cr ||||||||||| |
|---|
| 008 | 150406|2012||||xxc|||||o f|0| 0 eng|d |
|---|
| 040 | |aCaOODSP|beng |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aXC62-1/411-02E-PDF |
|---|
| 110 | 1 |aCanada. |bParliament. |bHouse of Commons. |bStanding Committee on Health. |
|---|
| 245 | 10|aDrug supply in Canada : |h[electronic resource]|ba multi-stakeholder responsibility / |cChair: Joy Smith, M.P. |
|---|
| 260 | |aOttawa - Ontario : |bHouse of Commons. |
|---|
| 300 | |a44p.|bfigs., references |
|---|
| 490 | 1 |aReport of the Standing Committee on Health|v41st Parliament, first session, ninth report |
|---|
| 500 | |aOriginal published on: 2012/06/08; published on: 2012/11/16. |
|---|
| 520 | 3 |aDuring meetings on 27 and 29 March, as well as 3 April 2012, the Committee heard from Health Canada officials, representatives of the pharmaceutical industry, healthcare professionals, pharmaceutical wholesalers and bulk purchasers, and patient advocates. This report outlines the role played by these stakeholders, summarizes the concerns that were expressed and offers recommendations that may mitigate future disruptions in the drug supply. |
|---|
| 590 | |a12-28|b2012-07-13 |
|---|
| 590 | |a12-47|b2012-11-23 |
|---|
| 690 | 07|aDrugs|2gcpds |
|---|
| 690 | 07|aPharmaceutical industry|2gcpds |
|---|
| 690 | 07|aSupply chain management|2gcpds |
|---|
| 775 | 08|tL'approvisionnement en médicaments au Canada : |w(CaOODSP)9.604359 |
|---|
| 776 | 0#|tDrug supply in Canada : |w(CaOODSP)9.555638 |
|---|
| 776 | 0#|tL'approvisionnement en médicaments au Canada : |w(CaOODSP)9.555639 |
|---|
| 830 | #0|aReport of the Standing Committee on Health ;|v41st Parliament, first session, ninth report|w(CaOODSP)9.507061 |
|---|
| 856 | 40|ahttp://publications.gc.ca|qPDF|s579 KB|uhttps://publications.gc.ca/collections/collection_2012/parl/XC62-1-411-02-eng.pdf|y41st Parliament, first session, ninth report |
|---|